球囊阻断逆行静脉血管栓塞术在肝硬化并发症治疗中的应用

辛丽霞; 朱洪宾; 刘笑; 张春清

doi:10.12449/JCH260228

球囊阻断逆行静脉血管栓塞术在肝硬化并发症治疗中的应用

DOI: 10.12449/JCH260228

辛丽霞¹,
朱洪宾²,
刘笑¹,
张春清^2, , ,

1.
山东省立医院消化内科，山东大学医学融合与实践中心，济南 250012
2.
山东第一医科大学附属省立医院消化内科，济南 250021

基金项目:

国家自然科学基金 (81970533)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：辛丽霞负责查阅、筛选文献，撰写论文；朱洪宾、刘笑辅助筛选文献；张春清负责论文撰写指导、审阅，最后定稿。

详细信息

通信作者:
张春清， ZHANG Chunqing_sdu@163.com （ORCID： 0000-0001-8711-1579）

计量
- 文章访问数: 11
- HTML全文浏览量: 2
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2025-05-20
- 录用日期: 2025-08-27
- 出版日期: 2026-02-25

Application of balloon-occluded retrograde transvenous obliteration in treatment of liver cirrhosis complications

1.
Department of Gastroenterology，Shandong Provincial Hospital，Medical Integration and Practice Center of Shandong University，Jinan 250012，China
2.
Department of Gastroenterology，Shandong Provincial Hospital Affiliated to Shandong First Medical University，Jinan 250021，China

Research funding:

National Natural Science Foundation of China (81970533)

More Information

Corresponding author: ZHANG Chunqing， zhangchunqing_sdu@163.com （ORCID： 0000-0001-8711-1579）

摘要

摘要: 胃静脉曲张破裂出血与肝性脑病是肝硬化失代偿期常见且危及生命的并发症。球囊阻断逆行静脉血管栓塞术作为一种微创介入技术，近年来在胃静脉曲张和肝性脑病的临床管理中取得显著进展。本文系统综述球囊阻断逆行静脉血管栓塞术的技术原理、适应证（如孤立性胃静脉曲张、难治性肝性脑病）、临床疗效（急性出血止血率85%～95%、1年再出血率<15%、肝性脑病改善率60%～80%）及安全性（包括肾功能损伤和门静脉压力升高等并发症）。同时，探讨球囊阻断逆行静脉血管栓塞术与传统治疗方式（如经颈静脉肝内门体分流术、内镜治疗）的利弊，并评述近年来的最新技术改良，如金属圈辅助逆行经静脉闭塞术、血管塞辅助逆行经静脉闭塞术。未来研究方向应聚焦于患者选择的精准化（如基于血流动力学参数的分层）、栓塞材料的优化（如新型可降解栓塞剂的应用）及个体化治疗方案的制订，从而在提高疗效的同时降低并发症风险。
- 气囊阻塞 /
- 肝硬化 /
- 食管和胃静脉曲张 /
- 肝性脑病
Abstract: Gastric variceal rupture and bleeding and hepatic encephalopathy are common and life-threatening complications in decompensated cirrhosis. As a minimally invasive interventional technique， balloon-occluded retrograde transvenous obliteration （BRTO） has made significant progress in the clinical management of gastric varices and hepatic encephalopathy in recent years. This article systematically reviews the technical principles， indications （e.g.， isolated gastric varices and refractory hepatic encephalopathy）， clinical efficacy （an acute hemostasis rate of 85% — 95%， a 1-year rebleeding rate of <15%， and an improvement rate of 60% — 80% for hepatic encephalopathy）， and safety （including complications such as renal impairment and elevated portal vein pressure） of BRTO. Meanwhile， this article discusses the advantages and disadvantages of BRTO and conventional treatment modalities （e.g.， transjugular intrahepatic portosystemic shunt and endoscopic treatment） and reviews the latest technological improvements in recent years， such as coil-assisted retrograde transvenous obliteration and plug-assisted retrograde transvenous obliteration. Future research should focus on the precision of patient selection （e.g.， stratification based on hemodynamic parameters）， the optimization of embolic materials （e.g.， application of new biodegradable embolic agents）， and the development of individualized treatment regimens， so as to improve efficacy and reduce the risk of complications.
- Balloon Occlusion /
- Liver Cirrhosis /
- Esophageal and Gastric Varices /
- Hepatic Encephalopathy

HTML全文

参考文献(51)

[1]	KANAGAWA H, MIMA S, KOUYAMA H, et al. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration[J]. J Gastroenterol Hepatol, 1996, 11( 1): 51- 58. DOI: 10.1111/j.1440-1746.1996.tb00010.x.
[2]	HIROTA S, MATSUMOTO S, TOMITA M, et al. Retrograde transvenous obliteration of gastric varices[J]. Radiology, 1999, 211( 2): 349- 356. DOI: 10.1148/radiology.211.2.r99ma25349.
[3]	KITAMOTO M, IMAMURA M, KAMADA K, et al. Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage[J]. AJR Am J Roentgenol, 2002, 178( 5): 1167- 1174. DOI: 10.2214/ajr.178.5.1781167.
[4]	CHIKAMORI F, KUNIYOSHI N, SHIBUYA S, et al. Eight years of experience with transjugular retrograde obliteration for gastric varices with gastrorenal shunts[J]. Surgery, 2001, 129( 4): 414- 420. DOI: 10.1067/msy.2001.112000.
[5]	TAKUMA Y, NOUSO K, MAKINO Y, et al. Prophylactic balloon-occluded retrograde transvenous obliteration for gastric varices in compensated cirrhosis[J]. Clin Gastroenterol Hepatol, 2005, 3( 12): 1245- 1252. DOI: 10.1016/s1542-3565(05)00744-5.
[6]	NINOI T, NISHIDA N, KAMINOU T, et al. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: Long-term follow-up in 78 patients[J]. AJR Am J Roentgenol, 2005, 184( 4): 1340- 1346. DOI: 10.2214/ajr.184.4.01841340.
[7]	CHO SK, SHIN SW, LEE IH, et al. Balloon-occluded retrograde transvenous obliteration of gastric varices: Outcomes and complications in 49 patients[J]. AJR Am J Roentgenol, 2007, 189( 6): W365- W372. DOI: 10.2214/AJR.07.2266.
[8]	HONG CH, KIM HJ, PARK JH, et al. Treatment of patients with gastric variceal hemorrhage: Endoscopic N-butyl-2-cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration[J]. J Gastroenterol Hepatol, 2009, 24( 3): 372- 378. DOI: 10.1111/j.1440-1746.2008.05651.x.
[9]	KATOH K, SONE M, HIROSE A, et al. Balloon-occluded retrograde transvenous obliteration for gastric varices: The relationship between the clinical outcome and gastrorenal shunt occlusion[J]. BMC Med Imaging, 2010, 10: 2. DOI: 10.1186/1471-2342-10-2.
[10]	IMAI Y, NAKAZAWA M, ANDO S, et al. Long-term outcome of 154 patients receiving balloon-occluded retrograde transvenous obliteration for gastric fundal varices[J]. J Gastroenterol Hepatol, 2016, 31( 11): 1844- 1850. DOI: 10.1111/jgh.13382.
[11]	KOBAYAKAWA M, KOKUBU S, HIROTA S, et al. Short-term safety and efficacy of balloon-occluded retrograde transvenous obliteration using ethanolamine oleate: Results of a prospective, multicenter, single-arm trial[J]. J Vasc Interv Radiol, 2017, 28( 8): 1108- 1115. e 2. DOI: 10.1016/j.jvir.2017.03.041.
[12]	SAAD WEA, KHAJA MS, HIROTA S. Balloon-occluded retrograde transvenous obliteration of gastric varices: Conception, evolution, and history[J]. Tech Vasc Interv Radiol, 2012, 15( 3): 160- 164. DOI: 10.1053/j.tvir.2012.07.002.
[13]	SAAD WEA, KITANOSONO T, KOIZUMI J, et al. The conventional balloon-occluded retrograde transvenous obliteration procedure: Indications, contraindications, and technical applications[J]. Tech Vasc Interv Radiol, 2013, 16( 2): 101- 151. DOI: 10.1053/j.tvir.2013.02.003.
[14]	OLSON E, YUNE HY, KLATTE EC. Transrenal-vein reflux ethanol sclerosis of gastroesophageal varices[J]. AJR Am J Roentgenol, 1984, 143( 3): 627- 628. DOI: 10.2214/ajr.143.3.627.
[15]	GWON DI, KO GY, YOON HK, et al. Gastric varices and hepatic encephalopathy: Treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration: A primary report[J]. Radiology, 2013, 268( 1): 281- 287. DOI: 10.1148/radiol.13122102.
[16]	KIM YH, KIM YH, KIM CS, et al. Comparison of balloon-occluded retrograde transvenous obliteration(BRTO) using ethanolamine oleate(EO), BRTO using sodium tetradecyl sulfate(STS) foam and vascular plug-assisted retrograde transvenous obliteration(PARTO)[J]. Cardiovasc Intervent Radiol, 2016, 39( 6): 840- 846. DOI: 10.1007/s00270-015-1288-8.
[17]	GWON DI, KIM YH, KO GY, et al. Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy: A prospective multicenter study[J]. J Vasc Interv Radiol, 2015, 26( 11): 1589- 1595. DOI: 10.1016/j.jvir.2015.07.011.
[18]	LEE EW, SAAB S, GOMES AS, et al. Coil-assisted retrograde transvenous obliteration(CARTO) for the treatment of portal hypertensive variceal bleeding: Preliminary results[J]. Clin Transl Gastroenterol, 2014, 5( 10): e61. DOI: 10.1038/ctg.2014.12.
[19]	SARIN SK, LAHOTI D, SAXENA SP, et al. Prevalence, classification and natural history of gastric varices: A long-term follow-up study in 568 portal hypertension patients[J]. Hepatology, 1992, 16( 6): 1343- 1349. DOI: 10.1002/hep.1840160607.
[20]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII–Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
[21]	WAGURI N, HAYASHI M, YOKOO T, et al. Simultaneous combined balloon-occluded retrograde transvenous obliteration and partial splenic embolization for portosystemic shunts[J]. J Vasc Interv Radiol, 2012, 23( 5): 650- 657. DOI: 10.1016/j.jvir.2012.01.065.
[22]	KOITO K, NAMIENO T, NAGAKAWA T, et al. Balloon-occluded retrograde transvenous obliteration for gastric varices with gastrorenal or gastrocaval collaterals[J]. AJR American J Roentgenol, 1996, 167( 5): 1317- 1320. DOI: 10.2214/ajr.167.5.8911204.
[23]	NAESHIRO N, AIKATA H, KAKIZAWA H, et al. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration[J]. J Gastroenterol Hepatol, 2014, 29( 5): 1035- 1042. DOI: 10.1111/jgh.12508.
[24]	CHOI YS, LEE JH, SINN DH, et al. Effect of balloon-occluded retrograde transvenous obliteration on the natural history of coexisting esophageal varices[J]. J Clin Gastroenterol, 2008, 42( 9): 974- 979. DOI: 10.1097/MCG.0b013e318126c154.
[25]	ARAI H, ABE T, SHIMODA R, et al. Emergency balloon-occluded retrograde transvenous obliteration for gastric varices[J]. J Gastroenterol, 2005, 40( 10): 964- 971. DOI: 10.1007/s00535-005-1654-4.
[26]	EMORI K, TOYONAGA A, OHO K, et al. Balloon-occluded retrograde transvenous obliteration versus endoscopic injection sclerotherapy for isolated gastric varices: A comparative study[J]. Kurume Med J, 2014, 60( 3-4): 105- 113. DOI: 10.2739/kurumemedj.ms63009.
[27]	AKAHOSHI T, TOMIKAWA M, KAMORI M, et al. Impact of balloon-occluded retrograde transvenous obliteration on management of isolated fundal gastric variceal bleeding[J]. Hepatol Res, 2012, 42( 4): 385- 393. DOI: 10.1111/j.1872-034X.2011.00939.x.
[28]	ZHOU ZY, ZHANG MJ, HUANG Q, et al. Comparison of efficacy and safety between clip-assisted endoscopic cyanoacrylate injection and balloon-occluded retrograde transvenous obliteration in gastric fundal varices: A network Meta-analysis[J]. Chin J Gastroenterol Hepatol, 2023, 32( 6): 646- 652. DOI: 10.3969/j.issn.1006-5709.2023.06.010. 周智勇, 张明君, 黄勍, 等. 内镜下钛夹辅助组织胶注射与球囊阻塞逆行经静脉闭塞术治疗胃底静脉曲张效果及安全性对比: 网状Meta分析[J]. 胃肠病学和肝病学杂志, 2023, 32( 6): 646- 652. DOI: 10.3969/j.issn.1006-5709.2023.06.010.
[29]	LIU H, XU BK. Effect of retrograde venous embolization under balloon catheter occlusion in the treatment of patients with gastric variceal bleeding[J]. China Med Device Inf, 2023, 29( 10): 66- 68, 158. DOI: 10.15971/j.cnki.cmdi.2023.10.039. 刘海, 徐宝康. 球囊导管闭塞下逆行性静脉栓塞术治疗胃静脉曲张破裂出血患者的效果观察[J]. 中国医疗器械信息, 2023, 29( 10): 66- 68, 158. DOI: 10.15971/j.cnki.cmdi.2023.10.039.
[30]	GARCIA-PAGÁN JC, BARRUFET M, CARDENAS A, et al. Management of gastric varices[J]. Clin Gastroenterol Hepatol, 2014, 12( 6): 919- 928. e 1. DOI: 10.1016/j.cgh.2013.07.015.
[31]	MIYAMOTO Y, OHO K, KUMAMOTO M, et al. Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension[J]. J Gastroenterol Hepatol, 2003, 18( 8): 934- 942. DOI: 10.1046/j.1440-1746.2003.03087.x.
[32]	WAGURI N, OSAKI A, WATANABE Y, et al. Balloon-occluded retrograde transvenous obliteration for gastric varices improves hepatic functional reserve in long-term follow-up[J]. JGH Open, 2021, 5( 12): 1328- 1334. DOI: 10.1002/jgh3.12675.
[33]	HIROTA S, KOBAYASHI K, KAKO Y, et al. Balloon-occluded retrograde transvenous obliteration of varices: Focusing on the portal hemodynamics and the recent techniques[J]. Hepatol Int, 2018, 12( Suppl 1): 102- 111. DOI: 10.1007/s12072-017-9813-2.
[34]	SAAD WEA, DARCY MD. Transjugular intrahepatic portosystemic shunt(TIPS) versus balloon-occluded retrograde transvenous obliteration(BRTO) for the management of gastric varices[J]. Semin Intervent Radiol, 2011, 28( 3): 339- 349. DOI: 10.1055/s-0031-1284461.
[35]	PARK JK, SAAB S, KEE ST, et al. Balloon-occluded retrograde transvenous obliteration(BRTO) for treatment of gastric varices: Review and meta-analysis[J]. Dig Dis Sci, 2015, 60( 6): 1543- 1553. DOI: 10.1007/s10620-014-3485-8.
[36]	WAGURI N, OSAKI A, WATANABE Y. Balloon-occluded retrograde transvenous obliteration for treatment of gastric varices[J]. World J Hepatol, 2021, 13( 6): 650- 661. DOI: 10.4254/wjh.v13.i6.650.
[37]	KHAKWANI A, TRIVEDI M, AFZAL M, et al. Use of balloon occluded retrograde transvenous obliteration(BRTO) for treatment of gastric varices: A narrative review[J]. Cureus, 2023, 15( 4): e38233. DOI: 10.7759/cureus.38233.
[38]	HU XD, BA XT, ZHU P. Risk factors and prognosis analysis of secondary hepatic encephalopathy in decompensated liver cirrhosis[J]. J Clin Exp Med, 2024, 23( 1): 9- 12. DOI: 10.3969/j.issn.1671-4695.2024.01.003. 胡向党, 巴晓彤, 朱萍. 肝硬化失代偿期继发肝性脑病的危险因素及预后分析[J]. 临床和实验医学杂志, 2024, 23( 1): 9- 12. DOI: 10.3969/j.issn.1671-4695.2024.01.003.
[39]	FERENCI P, LOCKWOOD A, MULLEN K, et al. Hepatic encephalopathy: Definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998[J]. Hepatology, 2002, 35( 3): 716- 721. DOI: 10.1053/jhep.2002.31250.
[40]	LEE EW, LEE AE, SAAB S, et al. Retrograde transvenous obliteration(RTO): A new treatment option for hepatic encephalopathy[J]. Dig Dis Sci, 2020, 65( 9): 2483- 2491. DOI: 10.1007/s10620-020-06050-7.
[41]	KATO T, UEMATSU T, NISHIGAKI Y, et al. Therapeutic effect of balloon-occluded retrograde transvenous obliteration on portal-systemic encephalopathy in patients with liver cirrhosis[J]. Intern Med, 2001, 40( 8): 688- 691. DOI: 10.2169/internalmedicine.40.688.
[42]	MUKUND A, CHALAMARLA LK, SINGLA N, et al. Intractable hepatic encephalopathy in cirrhotic patients: Mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration[J]. Eur Radiol, 2020, 30( 6): 3462- 3472. DOI: 10.1007/s00330-019-06644-4.
[43]	INOUE H, EMORI K, TOYONAGA A, et al. Long term results of balloon-occluded retrograde transvenous obliteration for portosystemic shunt encephalopathy in patients with liver cirrhosis and portal hypertension[J]. Kurume Med J, 2014, 61( 1-2): 1- 8. DOI: 10.2739/kurumemedj.MS63014.
[44]	FUKUDA T, HIROTA S, SUGIMURA K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy[J]. J Vasc Interv Radiol, 2001, 12( 3): 327- 336. DOI: 10.1016/s1051-0443(07)61912-5.
[45]	NISHI A, KENZAKA T, SOGI M, et al. Treatment of portosystemic shunt-borne hepatic encephalopathy in a 97-year-old woman using balloon-occluded retrograde transvenous obliteration: A case report[J]. World J Clin Cases, 2023, 11( 4): 945- 951. DOI: 10.12998/wjcc.v11.i4.945.
[46]	LI XY, LI JJ, SUN W. Establishment and evaluation of a nomogram prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis and esophagogastric variceal bleeding[J]. J Clin Hepatol, 2024, 40( 8): 1605- 1611. DOI: 10.12449/JCH240816. 李欣忆, 李娇娇, 孙蔚. 肝硬化食管胃底静脉曲张破裂出血患者经颈静脉肝内门体分流术后发生显性肝性脑病的列线图预测模型建立及评价[J]. 临床肝胆病杂志, 2024, 40( 8): 1605- 1611. DOI: 10.12449/JCH240816.
[47]	KIM T, YANG H, LEE CK, et al. Vascular plug assisted retrograde transvenous obliteration(PARTO) for gastric Varix Bleeding patients in the emergent clinical setting[J]. Yonsei Med J, 2016, 57( 4): 973- 979. DOI: 10.3349/ymj.2016.57.4.973.
[48]	PATEL RK, TRIPATHY T, PANIGRAHI MK, et al. Is salvage Plug-Assisted Retrograde Transvenous Obliteration(PARTO) safe and effective for bleeding gastric varices-A preliminary single-center experience[J]. Emerg Radiol, 2024, 31( 3): 359- 365. DOI: 10.1007/s10140-024-02232-2.
[49]	CHANG MY, KIM MD, KIM T, et al. Plug-assisted retrograde transvenous obliteration for the treatment of gastric variceal hemorrhage[J]. Korean J Radiol, 2016, 17( 2): 230- 238. DOI: 10.3348/kjr.2016.17.2.230.
[50]	LEE EW, SAAB S, EGHBALIEH N, et al. Coil or plug-assisted retrograde transvenous obliteration(CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multicenter, real-world 10-year retrospective study[J]. Hepatology, 2025, 82( 6): 1498- 1511. DOI: 10.1097/HEP.0000000000001255.
[51]	SAAD WEA, AL-OSAIMI AMS, CALDWELL SH. Pre-and post-balloon-occluded retrograde transvenous obliteration clinical evaluation, management, and imaging: Indications, management protocols, and follow-up[J]. Tech Vasc Interv Radiol, 2012, 15( 3): 165- 202. DOI: 10.1053/j.tvir.2012.07.003.